Workers may be unknowingly spreading 'deadly hospital superbugs' with common habit
According to British researchers, washing uniforms at home after work could fail to remove antibiotic-resistant bacteria from clothes.
In a new study by scientists at De Montfort University in Leicester, they found that washing machine biofilms may harbour pathogens and antibiotic resistance genes, which could be potential sources of bacterial contamination.
READ MORE: Can hot drinks actually cool you down during a heatwave?
READ MORE: Sunbed addict, 21, was told he could have 'a year to live'
Study leader Professor Katie Laird, of De Montfort University said: "Our research shows that domestic washing machines often fail to disinfect textiles, allowing antibiotic-resistant bacteria to survive.
"If we're serious about transmission of infectious disease via textiles and tackling antimicrobial resistance, we must rethink how we launder what our healthcare workers wear."
Antibiotic resistance is believed to be one of the biggest threats to global public health. The UK Health Security Agency (UKHSA) says there were an estimated 66,730 serious antibiotic-resistant infections in 2023 – a jump from 62,314 seen in 2019.
It warns that bacteria's growing resistance to antibiotics, which caused 1.14 million deaths across the globe in 2021 alone, could claim an additional 39 million lives in the next 25 years.
Existing research shows that bacteria can be transmitted through clothing. Hospital-acquired infections are a major health threat because they often involve antibiotic resistant bacteria, which are significantly harder to treat.
The authors of the study have warned that washing healthcare workers' uniforms at home in standard washing machines could be fuelling this threat.
Prof Laird said: "Together, the findings suggest that many home washing machines may be insufficient for decontaminating healthcare worker uniforms, and may be contributing to the spread of hospital-acquired infections and antibiotic resistance."
The latest study evaluated whether six models of home washing machine successfully decontaminated healthcare worker uniforms. It found that half of the machines did not disinfect the clothing during a rapid cycle, while a third failed to clean sufficiently during the standard cycle.
The team also analysed the biofilms – sticky bacterial growth on washing machine surfaces – of 12 machines and found the presence of potentially pathogenic bacteria and antibiotic resistance genes.
The research also showed that bacteria can develop resistance to domestic detergent, increasing their resistance to certain antibiotics.
The researchers have called for a revision of laundering guidelines given to healthcare workers.
Prof Laird added: "Alternatively, healthcare facilities could use on-site industrial machines to launder uniforms to improve patient safety and control the spread of antibiotic-resistant pathogens."
The study was published in the journal PLOS One.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
3 hours ago
- USA Today
Dangerous dams: Where are the six most at risk of failing in the US?
The number of dams at risk of overtopping is increasing, "threatening their structural integrity and downstream communities," according to a new study. The number of dams in the United States at risk of overtopping is increasing, "threatening their structural integrity and downstream communities," according to a new study from Florida researchers. About 250,000 people in three states live downstream of those dams, the researchers found. Published July 21, the study analyzed five decades of water-level data across 33 strategically selected dam sites to quantify how overtopping probability has evolved since 1973. "We identified six dams having the greatest overtopping probability, with several being located near large population centers, posing potential risks to the downstream communities," warned the study, published in the peer-reviewed British journal Nature Communications. "All six dams are classified as large and high-hazard potential." Where are the most at-risk dams located? The six dams with the highest probability of overtopping and the closest downstream cities were all located in Texas, Kansas and California: According to Florida State University scientists, this geographic distribution shows that certain regions are particularly vulnerable to changing weather patterns, such as more-frequent extreme rainfall. Aging infrastructure a concern Many U.S. dams were built nearly a century ago. Aging construction and changing hazards add to the risk for this crucial infrastructure. "In its 2025 infrastructure report card, the American Society of Civil Engineers gave U.S. dams a D+ rating, underscoring the urgency of reassessment and modernization," according to a statement from Florida State University. 'Decades ago, dam builders used the best available technology knowledge, but things have been changing, so aging infrastructure is something that is a concern,' said study co-author Ebrahim Ahmadisharaf, an assistant professor in the Florida A&M/Florida State University College of Engineering. 'In this study, we showed where hazards from overtopping are greatest, both because of risk of occurrence and possible consequences. It is a guide to where infrastructure spending could have the greatest impact,' he said. 31 of 33 dams studied were 'high-hazard' Of the 33 dams studied, 31 dams were classified as 'high hazard' by the Federal Emergency Management Agency (FEMA), meaning their failure could result in loss of life. 'We have to plan upfront for this potential risk,' Ahmadisharaf said. 'This information can help dam managers to consider whether they need to revisit their emergency action plans and strategy for operating dams.' What is 'overtopping?' In the study, "we defined dam overtopping as water levels rising uncontrollably above the dam crest, which may or may not lead to catastrophic failure." Overtopping occurs when stored water exceeds the capacity of a reservoir and spills over the top. This does not necessarily result in immediate damage or failure, but it weakens the dam structure and can increase the risk of catastrophic failure if it continues. Overtopping because of inadequate spillway design, debris blockage of spillways or settlement of the dam crest accounts for about 34% of all dam failures in the United States, according to the Association of State Dam Safety Officials. Dams have an important role in mitigating flood damages by regulating flow and storing excess water during periods of heavy precipitation. "However, they also pose a substantial risk of catastrophic failure when they become subject to hydrologic extreme events, such as floods that are exacerbated by climate change," the study reports. 'Uniquely severe' risk "Dam failures are uniquely severe compared to other infrastructure failures due to their potentially extensive damages to the economy, society, and ecosystem," the study said. "For example, in 2017, the spillway failure of Oroville Dam in California, the tallest dam in the United States, led to over 180,000 evacuations while the 2020 failure of Edenville and Sanford Dams in Michigan forced about 11,000 residents to evacuate, damaged over 3,000 homes, and incurred substantial recovery costs," the study said. "In 2024, Hurricane Helene caused flooding in North Carolina, where Lake Lure Dam partially overtopped, leading to evacuations in Rutherford County and over 25 swift water rescues." Study co-author Eunsaem Cho, a former FSU postdoctoral researcher who is now a research associate at NASA Goddard Space Flight Center, said, 'this study represents the first step toward a comprehensive assessment of dam overtopping probabilities in the U.S. Understanding this potential risk is crucial for protecting communities and prioritizing dam rehabilitation before catastrophic failures occur.'
Forbes
8 hours ago
- Forbes
UK Announces Deal With OpenAI To Augment Public Services And AI Power
UK and OpenAI Announce a new MOU OpenAI and the United Kingdom's Department for Science, Innovation and Technology signed a joint memorandum of understanding yesterday that sets out an ambitious joint plan to put OpenAI's models to work in day-to-day government tasks, to build new computing hubs on British soil, and to share security know-how between company engineers and the UK's AI Safety Institute. The agreement is voluntary and doesn't obligate the UK in any exclusive manner, yet the commitments are concrete: both sides want pilot projects running inside the civil service within the next twelve months. Details of the Joint MOU The memorandum identifies four key areas of joint innovation. It frames AI as a tool to raise productivity, speed discovery and tackle social problems, provided the public is involved so trust grows alongside capability. The partners will look for concrete deployments of advanced models across government and business, giving civil servants, small firms and start-ups new ways to navigate rules, draft documents and solve hard problems in areas such as justice, defence and education. To run those models at scale, they will explore UK-based data-centre capacity, including possible 'AI Growth Zones,' so critical workloads remain onshore and available when demand peaks. Finally, the deal deepens technical information-sharing with the UK AI Security Institute, creating a feedback loop that tracks emerging capabilities and risks and co-designs safeguards to protect the public and democratic norms. OpenAI also plans to enlarge its London office, currently at more than 100 staff, to house research and customer-support AI CEO Sam Altman has long been interested in the UK as a region for AI development because of the UK's long history in AI research, most notably starting with Alan Turing. 'AI will be fundamental in driving the change we need to see across the country, whether that's in fixing the NHS, breaking down barriers to opportunity or driving economic growth,' said UK Technology Secretary, Peter Kyle. 'That's why we need to make sure Britain is front and centre when it comes to developing and deploying AI, so we can make sure it works for us.' Altman echoed the ambition, calling AI 'a core technology for nation building' and urging Britain to move from planning to delivery. The Increasing Pace of Governmental AI Adoption and Funding Universities in London, Cambridge and Oxford supply a steady stream of machine-learning talent. Since the Bletchley Park summit in 2023, the UK has positioned itself as a broker of global safety standards, giving investors a sense of legal stability. And with a sluggish economy, ministers need a credible growth story; large-scale automation of paperwork is an easy pitch to voters. The UK offers scientists clear rules and public money. The UK government has already promised up to £500 million for domestic compute clusters and is reviewing bids for 'AI Growth Zones'. Three factors explain the timing. The UK is not alone in its AI ambitions. France has funnelled billions into a joint venture with Mistral AI and Nvidia, while Germany is courting Anthropic after its own memorandum with DSIT in February. The UK believes its head start with OpenAI, still the best-known brand in generative AI, gives it an edge in landing commercial spin-offs and high-paid jobs. Risks that could derail the plan Kyle knows that any mis-step, such as an AI bot giving faulty benefit advice, could sink trust. That is why the memorandum pairs deployment with security research and reserves the right for civil-service experts to veto outputs that look unreliable. The UK has had a long history with AI, and the risks posed by lack of progress. Notably, the infamous Lighthill report in 1973 was widely credited with contributing the first 'AI Winter', a marked period of decline of interest and funding in AI. As such, careful political consideration of AI is key to ensuring ongoing support. Public-sector unions may resist widespread automation, arguing that AI oversight creates as much work as it saves. Likewise there is widespread concern of vendor lock-in with the deal with OpenAI. By insisting on locally owned data centres and keeping the MOU open to additional suppliers, ministers hope to avoid a repeat of earlier cloud contracts that left sensitive workloads offshore and pricy relationships locked in. Finally, a single headline error, such as a chatbot delivering wrong tax guidance, for instance, could spark calls for a pause. However, the benefits currently outweigh the risks. No department stands to gain more than the UK's National Health Service, burdened by a record elective-care backlog. Internal modelling seen by officials suggests that automated triage and note-summarisation tools could return thousands of clinical hours each week. If early pilots succeed, hospitals in Manchester and Bristol will be next in line. And OpenAI is not new to the UK government. A chatbot for small businesses has been live for months, and an internal assistant nicknamed 'Humphrey' now drafts meeting notes and triages overflowing inboxes. Another tool, 'Consult,' sorts thousands of public submissions in minutes, freeing policy teams for higher-level work. The new agreement aims to lift these trials out of the margins and weave them more fully into the fabric of government. What's Next Joint project teams will start by mapping use-cases in justice, defence and social care. They must clear privacy impact assessments before live trials begin. If those trials shave measurable hours off routine tasks, the Treasury plans to set aside money in the 2026 Autumn Statement for a phased rollout. UK's agreement with OpenAI is an experiment in modern statecraft. It tests whether governmental organizations can deploy privately built, high-end models while keeping control of data and infrastructure. Success would mean delivering the promised benefits while avoiding the significant risks. Failure would reinforce arguments that large language models remain better at publicity than at public service.
Yahoo
10 hours ago
- Yahoo
AstraZeneca pledges $50bn investment in the US amid 200% tariff fears
AstraZeneca will invest $50 billion (€42.8 bn) in the US by 2030 in a move to expand its R&D and manufacturing there, the firm announced on Monday. This comes as the pharmaceutical giant aims to reach the target of $80 billion (€68.5 bn) in revenue by 2030, with 50% of it hoped to come from the US. The announcement also comes as the Trump administration threatens tariffs of up to 200% on drugs that are produced outside of the US. The new investment announcement is in addition to the $3.5 billion (€3 bn) pledged in November 2024. According to a statement from the company, the US plays a 'critical role' in AstraZeneca's ability 'to launch 20 new medicines by the end of the decade'. What will AstraZeneca produce in the US? As part of the investment, the British-Swedish company plans to build a new multi-billion dollar manufacturing facility in the state of Virginia. This plant will focus on the production of treatments for chronic diseases and is the largest single investment into a facility the company has ever made. '[This] announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally,' Pascal Soriot, Chief Executive Officer at AstraZeneca said in a statement from the company. 'I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines.' Related Revolut to create 400 new jobs as Paris HQ leads hopes towards French banking licence Universal Music Group confidentially files for US stock market listing The site in Virginia will have a particular focus on producing substances which make up AstraZeneca's weight management and metabolic treatment portfolio. As well as the site in Virginia, the investment will help expand facilities and production in Massachusetts, Maryland, California, Indiana and Texas, as well as finding new sites for clinical trials. AstraZeneca already has 19 R&D, manufacturing and commercial sites in the US, and the country is the company's largest market, representing 42% of their revenue. The firm currently employs more than 18,000 people and supports 92,000 jobs across the US. The new investment announcement is expected to create tens of thousands more jobs in the coming years. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
